Compare AU

Compare INCM vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

BetaShares Global Income Leaders ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Income Leaders ETF (INCM) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

INCM

CURE

Popularity

Low

Low

Pearlers invested

13

85

Median incremental investment

$1,240.50

$616.00

Median investment frequency

Monthly

Monthly

Median total investment

$4,610.40

$1,464.40

Average age group

> 35

> 35


Key Summary

INCM

CURE

Strategy

INCM.AX was created on 2018-10-18 by BetaShares. The fund's investment portfolio concentrates primarily on high dividend yield equity. The fund aims to track the performance of an index (before fees and expenses) that comprises 100 high-yielding global companies (ex-Australia) selected for their potential to generate attractive and sustainable income.

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

ALTRIA GROUP INC (3.34 %)

AT&T INC (2.08 %)

VERIZON COMMUNICATIONS INC (1.92 %)

Incyte Corp (3.14 %)

United Therapeutics Corp (2.87 %)

Gilead Sciences Inc (2.86 %)

Top 3 industries

Other (30.45 %)

Utilities (24.29 %)

Consumer Staples (11.82 %)

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

Management fee

0.45 %

0.45 %


Key Summary

INCM

CURE

Issuer

BetaShares

Global X

Tracking index

Nasdaq Global Income Leaders Index - USD-US Dollar

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.45 %

0.45 %

Price

$18.28

$52.66

Size

$32.016 million

$39.185 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.13 %

4.24 %

Market

ASX

ASX

First listed date

22/10/2018

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

INCM

CURE

Popularity

Low

Low

Pearlers invested

13

85

Median incremental investment

$1,240.50

$616.00

Median investment frequency

Monthly

Monthly

Median total investment

$4,610.40

$1,464.40

Average age group

> 35

> 35


Pros and Cons

INCM

CURE

Pros

  • Higher price growth

  • Higher distribution yield

Cons

  • Lower distribution yield

  • Lower price growth

INCM

CURE

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield

Home